Paper Details

  1. Home
  2. Paper Details

PLM-101 is a novel and potent FLT3/RET inhibitor with less adverse effects in the treatment of acute myeloid leukemia.

Author: ChoiHyoyi, ChoiYong June, KangKeon Wook, KimJi Won, KimMyung Jin, KimYong-Chul, KimYoon-Gyoon, OhSu-Jin, ParkJaewoo, ParkJin-Hee, ParkMiso

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study introduces PLM-101, a new drug that targets both FLT3 and RET kinases, which are involved in acute myeloid leukemia (AML). PLM-101 showed potent anti-leukemic activity in vitro and in vivo, suggesting it could be a potential treatment option for AML.
Paper Details　
Original Abstract of the Article :
Acute myeloid leukemia (AML) is a prevalent form of leukemia in adults. As its survival rate is low, there is an urgent need for new therapeutic options. In AML, FMS-like tyrosine kinase 3 (FLT3) mutations are common and have negative outcomes. However, current FLT3-targeting agents, Midostaurin and...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.biopha.2023.115066

データ提供：米国国立医学図書館（NLM）

A Promising New Treatment for Acute Myeloid Leukemia

This study presents a novel therapeutic agent, PLM-101, for the treatment of acute myeloid leukemia (AML). The researchers investigated PLM-101's ability to target two critical oncogenes, FLT3 and RET, which play a significant role in AML development.

They found that PLM-101 effectively inhibits FLT3 kinase, disrupting the signaling pathways that drive AML cell growth. Importantly, PLM-101 also inhibits RET, which indirectly leads to the degradation of FLT3 protein. This dual-targeting approach provides a more effective strategy for combating AML compared to current FLT3-specific therapies.

A New Hope for AML Patients

The study's findings offer a potential breakthrough in AML treatment. PLM-101, with its dual-targeting mechanism and promising safety profile, shows great potential as a new therapeutic option for patients with this aggressive form of leukemia.

The Importance of Ongoing Research in AML

This research highlights the critical need for ongoing research and development of new therapies for AML. PLM-101's success demonstrates the potential of targeting multiple oncogenes to overcome the challenges of drug resistance and adverse effects.

Dr.Camel's Conclusion

This study presents a promising new approach to treating AML by targeting both FLT3 and RET. PLM-101's dual-targeting mechanism and favorable safety profile make it a potential game-changer in the fight against this devastating disease.

Date :
  1. Date Completed 2023-08-17
  2. Date Revised 2023-08-17
Further Info :

Pubmed ID

37392657

DOI: Digital Object Identifier

10.1016/j.biopha.2023.115066

Related Literature

Article Analysis
・Effects of gilteritinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.